U.S. markets open in 1 hour 8 minutes

iBio, Inc. (IBIO)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.2750-0.0061 (-2.17%)
At close: 04:00PM EDT
0.2890 +0.01 (+5.09%)
Pre-Market: 08:21AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.2811
Bid0.2650 x 1400
Ask0.2900 x 3100
Day's Range0.2720 - 0.2870
52 Week Range0.2200 - 1.3400
Avg. Volume2,724,922
Market Cap59.996M
Beta (5Y Monthly)-4.28
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iBio, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Motley Fool

    iBio (IBIO) Q3 2022 Earnings Call Transcript

    Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements regarding our current expectations and projections about future events that are subject to risks and uncertainties. No forward-looking statements can be guaranteed and actual results may differ from the results discussed in the forward-looking statements.

  • Benzinga

    iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

    iBio Inc (NYSE: IBIO) received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company's lead COVID-19 vaccine program. In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (N) protein. It plans to file an IND application before the end of calendar 2022. The Company previously reported completing extensive preclinical studies and identifying

  • Insider Monkey

    10 Biotech Penny Stocks to Buy Now

    In this article, we discuss the 10 biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Biotech Penny Stocks to Buy Now. The fears around the spread of the coronavirus have returned to haunt people around the world as governments scramble to […]